A novel hydroxamic acid derivative, MHY218, induces apoptosis and cell cycle arrest through downregulation of NF-κB in HCT116 human colon cancer cells

International Journal of Oncology

Volumn 44, Issue 1, 2014, Pages 256-264

  Kim, Mi Kyeong ^a   Kang, Yong Jung ^a   Kim, Dong Hwan ^a   Hossain, Mohammad Akbar ^a,b   Jang, Jung Yoon ^a   Lee, Sun Hwa ^a   Yoon, Jeong Hyun ^a   Chun, Pusoon ^c   Moon, Hyung Ryong ^a   Kim, Hyung Sik ^d   Chung, Hae Young ^a   Kim, Nam Deuk ^a  

^a Pusan National University   (South Korea)

^b UMM AL QURA UNIVERSITY   (Saudi Arabia)

^c Inje University   (South Korea)

^d Sungkyunkwan University   (South Korea)

Author keywords

Apoptosis; Cell cycle; Colon cancer cells; Hydroxamic acid derivative; NF B

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOOXYGENASE 2; GELATINASE B; HYDROXAMIC ACID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MHY 218; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; PROTEIN P85; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL GROWTH; CELL NUCLEUS; CELL STRAIN HCT116; CELL SURVIVAL; CELL VIABILITY; CHEMOPROPHYLAXIS; COLON CANCER; CONCENTRATION RESPONSE; DNA DEGRADATION; DNA FRAGMENTATION; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN B1; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; HYDROXAMIC ACIDS; NF-KAPPA B; PHENYL ETHERS; PIMELIC ACIDS; RHO GTP-BINDING PROTEINS;

EID: 84891920184     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2163     Document Type: Article

References (34)

1. Hwang HJ, Kang YJ, Hossain MA, et al: Novel dihydrobenzofuro[4,5-b][1,8] naphthyridin-6-one derivative, MHY-449, induces apoptosis and cell cycle arrest in HCT116 human colon cancer cells. Int J Oncol 41: 2057-2064, 2012.
2. National Cancer Information Center: Cancer incidence and death. Goyang. http://www.cancer.go.kr/mbs/cancer. Accessed July 21, 2013.
3. Kelly C and Cassidy J: Chemotherapy in metastatic colorectal cancer. Surg Oncol 16: 65-70, 2007.
4. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
5. Sun SY, Hail N Jr and Lotan R: Apoptosis as a novel target for cancer chemoprevention. J Natl Cancer Inst 96: 662-672, 2004.
6. Aggarwal BB and Shishodia S: Suppression of the nuclear factorkappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann NY Acad Sci 1030: 434-441, 2004.
7. Horst D, Budczies J, Brabletz T, Kirchner T and Hlubek F: Invasion associated up-regulation of nuclear factor kappaB target genes in colorectal cancer. Cancer 115: 4946-4958, 2009.
8. Luo JL, Maeda S, Hsu LC, Yagita H and Karin M: Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6: 297-305, 2004.
9. Nandy P, Lien EJ and Avramis VI: Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis. Anticancer Res 19: 1625-1633, 1999.
10. Choudhary C, Kumar C, Gnad F, et al: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325: 834-840, 2009.
11. Walkinshaw DR and Yang XJ: Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 15: 237-243, 2008.
12. Mottet D and Castronovo V: Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis 25: 183-189, 2008.
13. Jeon HS, Ahn MY, Park JH, et al: Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells. Int J Oncol 37: 419-428, 2010.
14. Park JH, Ahn MY, Kim TH, et al: A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells. Invest New Drugs 30: 1887-1898, 2012.
15. Molinari M: Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 33: 261-274, 2000.
16. Niculescu AB, 3rd, Chen X, Smeets M, Hengst L, Prives C and Reed SI: Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18: 629-643, 1998.
17. Baus F, Gire V, Fisher D, Piette J and Dulic V: Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts. EMBO J 22: 3992-4002, 2003.
18. el-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
19. Gartel AL and Tyner AL: Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 246: 280-289, 1999.
20. Iannolo G, Conticello C, Memeo L and De Maria R: Apoptosis in normal and cancer stem cells. Crit Rev Oncol Hematol 66: 42-51, 2008.
21. Lorenzo HK and Susin SA: Therapeutic potential of AIF-mediated caspase-independent programmed cell death. Drug Resist Updat 10: 235-255, 2007.
22. Guo B, Godzik A and Reed JC: Bcl-G, a novel pro-apoptotic member of the Bcl-2 family. J Biol Chem 276: 2780-2785, 2001.
23. Harris MH and Thompson CB: The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 7: 1182-1191, 2000.
24. Lahiry L, Saha B, Chakraborty J, et al: Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells. Carcinogenesis 31: 259-268, 2010.
25. Kopp E and Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265: 956-959, 1994.
26. Spehlmann ME and Eckmann L: Nuclear factor-kappa B in intestinal protection and destruction. Curr Opin Gastroenterol 25: 92-99, 2009.
27. Bond M, Fabunmi RP, Baker AH and Newby AC: Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 435: 29-34, 1998.
28. Chopra A, Ferreira-Alves DL, Sirois P and Thirion JP: Cloning of the guinea pig 5-lipoxygenase gene and nucleotide sequence of its promoter. Biochem Biophys Res Commun 185: 489-495, 1992.
29. Nagaki M, Naiki T, Brenner DA, et al: Tumor necrosis factor alpha prevents tumor necrosis factor receptor-mediated mouse hepatocyte apoptosis, but not fas-mediated apoptosis: role of nuclear factor-kappaB. Hepatology 32: 1272-1279, 2000.
30. Wajant H, Pfizenmaier K and Scheurich P: Tumor necrosis factor signaling. Cell Death Differ 10: 45-65, 2003.
31. Mann JR and DuBois RN: Cyclooxygenase-2 and gastrointestinal cancer. Cancer J 10: 145-152, 2004.
32. Kim JH, Lee KW, Lee MW, Lee HJ, Kim SH and Surh YJ: Hirsutenone inhibits phorbol ester-induced upregulation of COX-2 and MMP-9 in cultured human mammary epithelial cells: NF-kappaB as a potential molecular target. FEBS Lett 580: 385-392, 2006.
33. Claria J and Romano M: Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr Pharm Des 11: 3431-3447, 2005.
34. Surh YJ, Chun KS, Cha HH, et al: Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res 480-481: 243-268, 2001.